1084-96-4

Usage

Uses

Used in Pain Relief Applications:
2,5-bis(acetyloxy)benzoic acid is used as an analgesic for the relief of minor aches and pains, such as headaches, muscle aches, and toothaches. It is effective in reducing pain by inhibiting the production of prostaglandins, which are responsible for pain and inflammation.
Used in Fever Reduction Applications:
2,5-bis(acetyloxy)benzoic acid is used as an antipyretic to reduce fever. It helps in lowering the body temperature by acting on the hypothalamus, the part of the brain responsible for temperature regulation.
Used in Inflammation Reduction Applications:
2,5-bis(acetyloxy)benzoic acid is used as an anti-inflammatory agent to decrease inflammation. It is effective in reducing the swelling and redness associated with various conditions, such as arthritis and sports injuries.
Used in Cardiovascular Health Applications:
2,5-bis(acetyloxy)benzoic acid is used as an antiplatelet agent to prevent blood clots. It reduces the risk of heart attacks and strokes by inhibiting the aggregation of platelets, which are essential for blood clot formation.
Used in Pharmaceutical Industry:
2,5-bis(acetyloxy)benzoic acid is used as a key ingredient in various forms of medication, such as tablets, chewable tablets, and effervescent tablets. It is readily available over-the-counter and is considered safe and effective when used as directed.

Upstream product

• 1194-98-5 2,5-Dihydroxybenzaldehyde 
• 108-24-7 acetic anhydride 
• 490-79-9 2,5-dihydroxybenzoic acid. 

Downstream Products

• 33757-85-6 methyl 2,5-diacetoxybenzoate 
• 37785-02-7 2,5-diacetoxybenzoyl chloride 
• 100136-53-6 2,5-dihydroxy-benzoic acid-[2]pyridylamide 
• 79365-88-1 2-acetoxy-5-hydroxy-benzoic acid 
• 52405-79-5 2,5-dihydroxy-N-phenylbenzamide 
• 84388-75-0 2,5-Diacetoxybenzoesaeure-N-hydroxysuccinimidester 
• 77008-84-5 2,5-Diacetoxybenzoesaeure-4-nitrophenylester 
• 69181-74-4 Acetic acid 4-acetoxy-2-ethoxycarbonyloxycarbonyl-phenyl ester 
• 5330-25-6 5-O-Acetylgentisinsaeure 
• 905584-23-8 4-(2,5-diacetoxybenzoyloxy)benzaldehyde 
• 905584-40-9 2,5-diacetoxy-benzoic acid 4-[bis-(4-hydroxy-2-oxo-2H-chromen-3-yl)-methyl]-phenyl ester 
• 875544-26-6 2,5-diacetoxy-benzoic acid 2-phenylselanyl-ethyl ester 
• 224432-10-4 N-benzyl-2,5-dihydroxybenzamide 
• 109017-06-3 N-acetyl-2,5-diacetoxybenzamide 

Relevant academic research and scientific papers

Hydrogen atom abstraction by synthetic heme ferric superoxide and hydroperoxide species

To date, artificial dioxygen adducts of heme have not been demonstrated to be able to oxidize organic substrates in sharp contrast to their non-heme analogues and naturally occurring enzymes like heme dioxygenases. To address this apparent anomaly, an iro

ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE

Disclosed herein are acylated active agents (e.g., acylated hydroxybenzoic acid), compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for

POLYMERIZABLE LIQUID CRYSTAL COMPOUND, COMPOSITION FOR OPTICAL FILM, AND OPTICAL FILM, COMPENSATION FILM, ANTIREFLECTIVE FILM, AND DISPLAY DEVICE INCLUDING THE SAME

A polymerizable liquid crystal compound represented by Chemical Formula 1: wherein in Chemical Formula 1, groups and variables are the same as defined in the detailed description.

SUBTANCES FOR THE PROTECTION OF CELLS AND/OR TISSUES

The invention relates to substances that are suitable for protecting cells and/or tissues.

Studies on depigmenting activities of dihydroxyl benzamide derivatives containing adamantane moiety

Six diphenolic compounds containing adamantane moiety were synthesized and evaluated as potent inhibitors on tyrosinase activity and melanin formation in melan-a cells. The inhibitory activity of 4-adamantyl resorcinol 1 was similar to that of 4-n-butyl resorcinol in both assays. However, dihydroxyl benzamide derivatives 6a-e showed different inhibitory patterns. All derivatives significantly suppressed the cellular melanin formation without tyrosinase inhibitory activities. These behaviors indicated that the introduction of amide bond changes the binding mode of dihydroxyl groups to tyrosinase. Among derivatives, 6d (3,4-dihydroxyl compound) and 6e (2,3-dihydroxyl compound) showed stronger inhibitory activities (IC50 = 1.25 μM and 0.73 μM, respectively) as compared to 4-n-butyl resorcinol (IC50 = 21.64 μM) and hydroquinone (IC50 = 3.97 μM). This study showed that the position of dihydroxyl substituent at aromatic ring is important for the intercellular inhibition of melanin formation, and also amide linkage and adamantane moiety enhance the inhibition.

HIV-1 integrase inhibition of biscoumarin analogues

Nineteen biscoumarins bearing free and modified hydroxyl substituents at benzoyloxyphenyl linker have been synthesized by multiple step synthesis. Among these biscoumarins, thirteen were found to be active molecules against HIV-1 integrase (HIV-1 IN). The structure-activity relationship of the nineteen compounds on HIV IN may be useful for the design of potent therapeutic agents.

Synthesis of selenium-containing polyphenolic acid esters and evaluation of their effects on antioxidation and 5-lipoxygenase inhibition

Six novel selenium-containing polyphenolic acid esters were synthesized and evaluated as antioxidants and 5-lipoxygenase inhibitors. Synthesis of the title compounds involved the Mitsunobu reaction of polyphenolic acids (4-8, 14) with 2-phenylselenoethanol (3). Compounds 22, 23, and 25 were found to be very effective antioxidants and 5-lipoxygenase inhibitors with activity comparable to or better than caffeic acid (3,4-dihydroxycinnamic acid) phenethyl ester (CAPE).

Novel quinolizidine salicylamide influenza fusion inhibitors

A novel series of quinolizidine salicylamides was synthesized as specific inhibitors of the H1 subtype of influenza A viruses. These inhibitors inhibit the pH-induced fusion process, thereby blocking viral entry into host cells. Compound 16 was the most active inhibitor in this series with an EC50 of 0.25 μg/mL in plaque reduction assay. The synthesis and the SAR of these compounds are discussed.

Novel Enzymatic De-esterification Studies on Substituted Polyacetoxybenzamides

The regioselective capabilities of porcine pancreatic lipase in tetrahydrofuran and Candida rugosa lipase in diisopropyl ether have been investigated for selective deacetylation of peracetates of primary, secondary and tertiary amides of 2-hydroxy-, 2,4-dihydroxy-, 2,5-dihydroxy-, 3,5-dihydroxy- and 3,4,5-trihydroxybenzoic acids. The lipases exhibit random selectivity for the deacetylation of ortho-, meta- and para-acetoxy functions of di/triacetoxybenzamides leading to the formation of the corresponding partially and/or completely deacetylated benzamides. The amide group of all substrates under investigation remains inert to enzymatic hydrolysis. The results of deesterification are in good agreement with our earlier proposed mechanism of action of porcine pancreatic lipase on diaryl or aryl alkyl ketones in organic solvents.

Analogs of 3-(1-Phenyl-3-oxobutyl)-4-hydroxycoumarin (Warfarin) Prepared from Substituted Salicylic Acids

Some derivatives of salicylic acid containing substituents meta to the carboxyl group were used to prepare analogs of the anticoagulant drug warfarin, 3-(1-phenyl-3-oxobutyl)-4-hydroxycoumarin, containing substituents in either the 6- or 8-position of the coumarin ring.When the substituent was the hydroxyl group, the resulting products are previously identified metabolites of warfarin.The substituted salicylic acid is first acetylated with acetic anhydride, then either converted to the acid chloride and condensed with diethyl malonate in the presence of sodium hydroxide or converted to the mixed anhydride with formic acid and condensed with ethoxymagnesium diethyl malonate to yield, in either case, the corresponding 3-carbethoxy-4-hydroxycoumarin substituted in the 6- or 8-position of the coumarin ring.These compounds readily condense with benzalacetone to form the corresponding substituted warfarin in the presence of 5 mole percent tertiary amine catalyst.This method offers an improved route for the synthesis or 8-hydroxywarfarin.